Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Thiogenesis Therapeutics Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1.62	3.85	7.08	6.2	0.06
Cash & Short-Term Investments	1.62	3.85	7.08	6.2	0.06
Cash Growth	-58.00%	-45.62%	14.21%	9805.77%	225.72%
Accounts Receivable	-	-	0.09	-	-
Other Receivables	0.08	0.09	-	0.06	0.17
Receivables	0.08	0.09	0.09	0.06	0.17
Prepaid Expenses	0.12	0.05	0.08	0.04	-
Total Current Assets	1.81	3.98	7.24	6.29	0.23
Total Assets	1.81	3.98	7.24	6.29	0.23
Accounts Payable	1.24	0.56	1.67	0.31	0.68
Accrued Expenses	-	-	0.04	-	0
Short-Term Debt	-	-	-	-	0.46
Other Current Liabilities	-	-	-	-	0.15
Total Current Liabilities	1.24	0.56	1.71	0.31	1.29
Total Liabilities	1.24	0.56	1.71	0.31	1.29
Common Stock	19.92	16.14	15.01	11.13	1.05
Additional Paid-In Capital	-	-	-	-	0.04
Retained Earnings	-21.71	-14.28	-11.14	-6.18	-2.14
Comprehensive Income & Other	2.36	1.57	1.66	1.03	-0.01
Shareholders' Equity	0.57	3.43	5.53	5.98	-1.06
Total Liabilities & Equity	1.81	3.98	7.24	6.29	0.23
Total Debt	-	-	-	-	0.46
Net Cash (Debt)	1.62	3.85	7.08	6.2	-0.4
Net Cash Growth	-58.00%	-45.62%	14.21%	-	-
Net Cash Per Share	0.03	0.08	0.18	0.24	-0.03
Filing Date Shares Outstanding	51.84	46.02	44.57	38.86	12
Total Common Shares Outstanding	51.84	46.02	44.57	38.86	12
Working Capital	0.57	3.43	5.53	5.98	-1.06
Book Value Per Share	0.01	0.07	0.12	0.15	-0.09
Tangible Book Value	0.57	3.43	5.53	5.98	-1.06
Tangible Book Value Per Share	0.01	0.07	0.12	0.15	-0.09

Source: S&P Global Market Intelligence. Standard template. Financial Sources.